562 related articles for article (PubMed ID: 33904154)
1. Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status.
Henter ID; Park LT; Zarate CA
CNS Drugs; 2021 May; 35(5):527-543. PubMed ID: 33904154
[TBL] [Abstract][Full Text] [Related]
2. Glutamatergic Modulators in Depression.
Henter ID; de Sousa RT; Zarate CA
Harv Rev Psychiatry; 2018; 26(6):307-319. PubMed ID: 29465478
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic Modulation of Glutamate Receptors in Major Depressive Disorder.
Jaso BA; Niciu MJ; Iadarola ND; Lally N; Richards EM; Park M; Ballard ED; Nugent AC; Machado-Vieira R; Zarate CA
Curr Neuropharmacol; 2017; 15(1):57-70. PubMed ID: 26997505
[TBL] [Abstract][Full Text] [Related]
4. A new generation of antidepressants: an update on the pharmaceutical pipeline for novel and rapid-acting therapeutics in mood disorders based on glutamate/GABA neurotransmitter systems.
Wilkinson ST; Sanacora G
Drug Discov Today; 2019 Feb; 24(2):606-615. PubMed ID: 30447328
[TBL] [Abstract][Full Text] [Related]
5. Ketamine and Beyond: Investigations into the Potential of Glutamatergic Agents to Treat Depression.
Lener MS; Kadriu B; Zarate CA
Drugs; 2017 Mar; 77(4):381-401. PubMed ID: 28194724
[TBL] [Abstract][Full Text] [Related]
6. New targets for rapid antidepressant action.
Machado-Vieira R; Henter ID; Zarate CA
Prog Neurobiol; 2017 May; 152():21-37. PubMed ID: 26724279
[TBL] [Abstract][Full Text] [Related]
7. Glutamatergic modulators: the future of treating mood disorders?
Zarate C; Machado-Vieira R; Henter I; Ibrahim L; Diazgranados N; Salvadore G
Harv Rev Psychiatry; 2010; 18(5):293-303. PubMed ID: 20825266
[TBL] [Abstract][Full Text] [Related]
8. Glutamate and its receptors in the pathophysiology and treatment of major depressive disorder.
Niciu MJ; Ionescu DF; Richards EM; Zarate CA
J Neural Transm (Vienna); 2014 Aug; 121(8):907-24. PubMed ID: 24318540
[TBL] [Abstract][Full Text] [Related]
9. Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders.
Hashimoto K; Malchow B; Falkai P; Schmitt A
Eur Arch Psychiatry Clin Neurosci; 2013 Aug; 263(5):367-77. PubMed ID: 23455590
[TBL] [Abstract][Full Text] [Related]
10. Mood Therapeutics: Novel Pharmacological Approaches for Treating Depression.
Henter ID; de Sousa RT; Gold PW; Brunoni AR; Zarate CA; Machado-Vieira R
Expert Rev Clin Pharmacol; 2017 Feb; 10(2):153-166. PubMed ID: 27781556
[TBL] [Abstract][Full Text] [Related]
11. The role of the tripartite glutamatergic synapse in the pathophysiology and therapeutics of mood disorders.
Machado-Vieira R; Manji HK; Zarate CA
Neuroscientist; 2009 Oct; 15(5):525-39. PubMed ID: 19471044
[TBL] [Abstract][Full Text] [Related]
12. Role of calcium, glutamate and NMDA in major depression and therapeutic application.
Deutschenbaur L; Beck J; Kiyhankhadiv A; Mühlhauser M; Borgwardt S; Walter M; Hasler G; Sollberger D; Lang UE
Prog Neuropsychopharmacol Biol Psychiatry; 2016 Jan; 64():325-33. PubMed ID: 25747801
[TBL] [Abstract][Full Text] [Related]
13. Rapid-acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective.
Hashimoto K
Psychiatry Clin Neurosci; 2019 Oct; 73(10):613-627. PubMed ID: 31215725
[TBL] [Abstract][Full Text] [Related]
14. Targeting of NMDA receptors in the treatment of major depression.
Dang YH; Ma XC; Zhang JC; Ren Q; Wu J; Gao CG; Hashimoto K
Curr Pharm Des; 2014; 20(32):5151-9. PubMed ID: 24410564
[TBL] [Abstract][Full Text] [Related]
15. Ketamine and other potential glutamate antidepressants.
Dutta A; McKie S; Deakin JFW
Psychiatry Res; 2015 Jan; 225(1-2):1-13. PubMed ID: 25467702
[TBL] [Abstract][Full Text] [Related]
16. Targeting glutamatergic signaling for the development of novel therapeutics for mood disorders.
Machado-Vieira R; Salvadore G; Ibrahim LA; Diaz-Granados N; Zarate CA
Curr Pharm Des; 2009; 15(14):1595-611. PubMed ID: 19442176
[TBL] [Abstract][Full Text] [Related]
17. Ketamine and its metabolite (2R,6R)-hydroxynorketamine induce lasting alterations in glutamatergic synaptic plasticity in the mesolimbic circuit.
Yao N; Skiteva O; Zhang X; Svenningsson P; Chergui K
Mol Psychiatry; 2018 Oct; 23(10):2066-2077. PubMed ID: 29158578
[TBL] [Abstract][Full Text] [Related]
18. NMDA antagonists under investigation for the treatment of major depressive disorder.
Pochwat B; Pałucha-Poniewiera A; Szewczyk B; Pilc A; Nowak G
Expert Opin Investig Drugs; 2014 Sep; 23(9):1181-92. PubMed ID: 24818801
[TBL] [Abstract][Full Text] [Related]
19. Ketamine and other glutamate receptor modulators for depression in bipolar disorder in adults.
McCloud TL; Caddy C; Jochim J; Rendell JM; Diamond PR; Shuttleworth C; Brett D; Amit BH; McShane R; Hamadi L; Hawton K; Cipriani A
Cochrane Database Syst Rev; 2015 Sep; (9):CD011611. PubMed ID: 26415966
[TBL] [Abstract][Full Text] [Related]
20. Can we increase the speed and efficacy of antidepressant treatments? Part II. Glutamatergic and RNA interference strategies.
Artigas F; Celada P; Bortolozzi A
Eur Neuropsychopharmacol; 2018 Apr; 28(4):457-482. PubMed ID: 29525411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
